Life sciences leaders who want a deeper view into global market access trends can complete the form below to receive Trinity’s annual State of Global Market Access white paper. The paper provides a cross-region view of how: The Trump administration’s…
Traditional commercial models, built on static call plans, product-led communication, and siloed execution, no longer deliver the relevance, responsiveness, and personalization that healthcare professionals (HCPs) expect. Generative and agentic AI promise smarter targeting, automated content, and self‑optimizing HCP journeys, but…
An industry research collaboration between Point of Care Marketing Association, Trinity, Syneractiv and MedFuse. POC Marketing is Being Systematically Undervalued Point of Care marketing now represents over $1 billion in annual U.S. healthcare advertising spend—yet most Marketing Mix Models (MMM)…
The 2024 cohort of pharmaceutical and biotechnology launches has set a new benchmark, according to analysis by Trinity Life Sciences, with 50% of new launches exceeding their first-year forecasts. Marked by innovative therapies, streamlined regulatory approvals, executional excellence and advanced…
Discover how Trinity Life Sciences is transforming pharma commercialization with generative AI (GenAI). In this white paper, experts share how Trinity’s GenAI-powered solutions are reshaping Medical Affairs, Field Insights, Competitive Intelligence and more—delivering faster insights, reducing friction and unlocking new…
Can artificial intelligence and machine learning (AIML) be used to support portfolio decision-making across the life sciences industry? In this installment of our Industry Impact Series, we find that not only can the latest AIML techniques identify the drivers of…
The 2023 launch class exceeded Trinity Life Sciences’ expectations with only 50% underperforming their pre-launch first year forecasts while 39% overperformed, indicating an improvement from prior years (54% and 35%, respectively, for 2020–2023). This was driven by notable improvements in “Specialty and Large Market” products (36% overperformed vs. 18% average in years prior) and First Launch Companies (33% overperformed vs. 20% in years prior). The needle is moving.
The National Reimbursement Drug List (NRDL) negotiations are expected to conclude by November 2024, with pricing outcomes gradually being revealed starting in January 2025. The Trinity Life Sciences team has reviewed the 2023 NRDL inclusion and pricing results, drawing some key learnings.
Demonstrating the value of Field Medical Affairs has, to date, been a challenge due to its qualitative and non-promotional nature. Traditional, activity-based metrics have missed the mark on translating Field Medical Affairs activities to tangible milestones, such as changes in…
Experts at Trinity Life Sciences interact with the inner workings of pharma from many perspectives as they engage with teams across life sciences organizations. A common observation is that teams are working in silos: often unaware of what other teams…